Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
- Conditions
- Glioma, Malignant
- Registration Number
- NCT05100602
- Lead Sponsor
- Genetron Health
- Brief Summary
The purpose of this trail is to evaluate the performance of Genetron TERT PCR Kit in Glioma patients using real-time PCR method.
- Detailed Description
This trial follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with the Genetron TERT PCR Kit and Sanger sequencing method. The results were determined independently according to the cutoff values or interpretation requirements provided by each method.Combined with the results of clinicopathological classification, the incidence of C228T and C250T mutations of TERT promoter genes in different subtypes was counted to evaluate the clinical application performance of the Genetron TERT PCR Kit.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1192
- Enroll cases in strict accordance with the requirements of the study
- The remaining samples after routine clinical testing
- The collection and processing of samples meet the requirements of standard laboratory operations and product instructions
- The relevant information of the sample is complete, including sample number, gender, age, and possible clinical diagnosis information
- Each sample must have HE staining results (hematoxylin-eosin staining)
- Pathological examination diagnosed as glioma, other brain tumors or normal tissues
- Number of samples: 10 pieces of each sample with a thickness of 10μm, and the tumor content is not less than 50%
- The sample information is not complete
- Severely contaminated samples
- Samples that do not meet the requirements of sample collection and processing
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of the Genetron TERT PCR Kit 3 months The main purpose of this study is: by evaluating the Genetron TERT PCR Kit to compare the results of the Sanger sequencing method, and to calculate the coincidence rate and consistency of the two methods.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
The First Hospital of Jilin University
🇨🇳Jilin, China
Huashan Hospital of Fudan University
🇨🇳Shanghai, China
West China Hospital of Sichuan University
🇨🇳Sichuan, China
The Second Affiliated Hospital of Zhejiang University
🇨🇳Zhejiang, China